 <h1>Viltepso Side Effects</h1><p class="drug-subtitle"><b>Generic Name:</b> <i>viltolarsen</i></p><ul class="nav-tabs nav-tabs-collapse nav-tabs-pill">
<li>Overview</li>
<li><b class="nav-item here">Side Effects</b></li>
<li>Dosage</li>
<li>Professional</li>
<li>Pregnancy</li>
<li class="nav-more">
More&lt;svg aria-hidden="true" class="ddc-icon ddc-icon-down" focusable="false" height="16" viewbox="0 0 24 24" width="16" xmlns="http://www.w3.org/2000/svg"&gt;&lt;path d="M18.5 7.94L19.56 9 12 16.56 4.44 9 5.5 7.94l6.5 6.5z"&gt;&lt;/path&gt;&lt;/svg&gt;
</li>
</ul><ul>
<li>Managing Side Effects</li>
</ul><p class="ddc-notification"><b>Note:</b> This document contains side effect information about viltolarsen. Some of the dosage forms listed on this page <em>may not</em> apply to the brand name Viltepso.</p><p><i>Applies to viltolarsen: intravenous solution</i></p><h3>General</h3><p>The most reported adverse reactions with this drug have included upper respiratory tract infection, injection site reaction, cough, and pyrexia.<sup>[Ref]</sup></p><h3>Respiratory</h3><p>Upper respiratory tract infection includes upper respiratory tract infection, nasopharyngitis, and rhinorrhea.</p><p><b>Very common</b> (10% or more): Upper respiratory tract infection (up to 63%), cough (19%)</p><h3>Local</h3><p>Injection site reactions include injection site bruising, injection site erythema, injection site reaction, and injection site swelling.</p><p><b>Very common</b> (10% or more): Injection site reaction (25%)</p><h3>Gastrointestinal</h3><p><b>Common</b> (1% to 10%): Diarrhea (13%), vomiting 13%, abdominal pain (13%)</p><h3>Renal</h3><p>Kidney toxicity, including potentially fatal glomerulonephritis, has been observed after administration of some antisense oligonucleotides.  To date, it has not been reported in clinical trials with this drug, but clinical experience is limited.  In juvenile male mice injected weekly with escalating doses of this drug, there was a dose-dependent increase in the incidence and severity of renal tubular effects (including degeneration), which were not accompanied by clinical pathology correlates.</p><p>Other antisense oligonucleotides: </p><p><b>Frequency not reported</b>: Kidney toxicity including potentially fatal glomerulonephritis</p><h3>Other</h3><p><b>Very common</b> (10% or more): Pyrexia (19%), contusion (13%)</p><h3>Musculoskeletal</h3><p><b>Very common</b> (10% or more): Arthralgia (13%)</p><h3>Dermatologic</h3><p><b>Very common</b> (10% or more): Urticaria (13%)</p><h3>Cardiovascular</h3><p><b>Very common</b> (10% or more): Ejection fraction decreased (13%)</p><p id="ref_1">1. "Product Information. Viltepso (viltolarsen)." NS Pharma, Paramus, NJ. </p><h2 class="ddc-anchor-offset" id="faq">Frequently asked questions</h2><ul>
<li>What is the mechanism of action?</li>
<li>How long does it take for Viltepso to work?</li>
<li>What are the new drugs for Duchenne muscular dystrophy?</li>
</ul><h2>More about Viltepso (viltolarsen)</h2><ul class="more-resources-list more-resources-list-general">
<li>During Pregnancy</li>
<li>Dosage Information</li>
<li>Pricing &amp; Coupons</li>
<li>Drug class: miscellaneous uncategorized agents</li>
<li>FDA Approval History</li>
</ul><h3>Consumer resources</h3><ul class="more-resources-list more-resources-list-consumer">
<li>Patient Information</li>
<li>Viltepso &lt;span&gt;(Advanced Reading)&lt;/span&gt;</li>
</ul><h3>Professional resources</h3><ul class="more-resources-list more-resources-list-professional">
<li>Prescribing Information</li>
<li data-more-config-id="list-data-resources-professional">... +1 more</li>
</ul><h3>Related treatment guides</h3><ul class="more-resources-list more-resources-list-conditions">
<li>Duchenne Muscular Dystrophy</li>
</ul><h2>Further information</h2><p class="ddc-disclaimer">Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.</p><p>Some side effects may not be reported. You may report them to the FDA.</p><p class="ddc-disclaimer-link">Medical Disclaimer</p>